Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521130-28-00

Acronym

80202135MYG3002

Enrollment

Registered

2025-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

generalized myasthenia gravis

Brief summary

Averaged mean percent change from baseline in total IgG over Weeks 8 to 12 between Arms 1 and 2.

Interventions

DRUGEFGARTIGIMOD ALFA

DRUGJNJ-80202135

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Averaged mean percent change from baseline in total IgG over Weeks 8 to 12 between Arms 1 and 2.	—

Countries

Austria, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026